Dayvigo (Lemborexant) Cost in California 2026: Prices, Insurance, and Savings

What Does Dayvigo Actually Cost in California?

The sticker price and the price you pay are rarely the same number. Eisai, the manufacturer, sets Dayvigo's wholesale acquisition cost near $320 per month for a 30-tablet supply at either the 5 mg or 10 mg strength. California retail pharmacies, after negotiation with wholesalers and pharmacy benefit managers, list an average cash-pay price of about $85 per month in 2026. That gap matters because the price you see depends entirely on how you pay.

The FDA-approved prescribing information for Dayvigo specifies two dose strengths: 5 mg and 10 mg, both taken once nightly no more than 7 minutes before bedtime [1]. California pharmacies stock both strengths, and per-tablet pricing is generally identical between doses. Patients without insurance should compare prices across chains. Tools like GoodRx and RxSaver aggregate California pharmacy pricing in real time. A patient in Los Angeles may find a different price than one in Sacramento, so checking multiple zip codes is worth the effort.

Cash-pay pricing in California also varies by pharmacy type. Independent pharmacies sometimes price below large chains, while mail-order pharmacies affiliated with insurers (such as OptumRx or Express Scripts) may offer 90-day supplies at a per-unit discount. The Eisai patient support page lists additional access programs [1].

Does California Medi-Cal Cover Dayvigo?

Yes, but not automatically. California's Medicaid program (Medi-Cal) lists Dayvigo on its formulary with a prior authorization (PA) requirement. That means your prescribing clinician must submit documentation to Medi-Cal demonstrating that you meet specific criteria before the plan will pay for the drug. The typical PA criteria for Dayvigo in California require documented insomnia diagnosis, failure of or contraindication to at least one first-line agent, and a clinician's attestation that the patient is not concurrently using other central nervous system depressants in a way that poses safety concerns.

The American Academy of Sleep Medicine clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacotherapy as an adjunct or second step [2]. Medi-Cal PA reviewers often reference this guideline. Having a trial of CBT-I documented in the chart can speed approval.

Processing time for Medi-Cal PA requests in California typically runs 24 to 72 hours for standard requests. Urgent requests can be expedited to within 24 hours if the prescriber certifies that delay could seriously jeopardize the patient's health. If denied, patients have the right to a fair hearing through the California Department of Health Care Services [3]. The DHCS Medi-Cal formulary search tool allows providers to verify current coverage status before prescribing [3].

How Does the Eisai Savings Card Work?

Eisai offers a manufacturer copay savings card for commercially insured patients filling Dayvigo prescriptions. The card can reduce out-of-pocket costs to as low as $0 per fill for eligible patients, depending on plan structure. This applies at California pharmacies that accept manufacturer copay cards, which includes most major chains.

Key eligibility rules: the patient must have commercial (private) insurance, not a government-funded plan such as Medi-Cal, Medicare Part D, or Tricare. The savings card typically has an annual cap on the total benefit (often $3,600 per year), after which the patient reverts to their plan's standard copay. The FDA's Orange Book listing for Dayvigo confirms the branded product's patent and exclusivity status, which is relevant because generic entry would change savings card dynamics [4].

Patients should ask their pharmacy to run the savings card as a secondary claim after insurance processes the primary claim. Some pharmacies in California do this automatically; others require the patient to present both cards at pickup. If you encounter a pharmacy that refuses the card, Eisai's support line can intervene.

Which Insurance Plans Cover Dayvigo in California?

Coverage varies by plan and tier. Most large commercial insurers operating in California (Blue Shield of California, Anthem Blue Cross, Kaiser Permanente, Health Net, and others) include Dayvigo on their formularies, though tier placement differs. Dayvigo most commonly sits on tier 3 (preferred brand) or tier 4 (non-preferred brand), which means copays range from $35 to $75 per fill before any savings card is applied.

Kaiser Permanente, which operates as both insurer and pharmacy in California, has its own formulary committee. Kaiser's Northern and Southern California regions sometimes differ on tier placement for the same drug. The SUNRISE-1 trial (N=1,006), which demonstrated that lemborexant 5 mg and 10 mg significantly improved sleep onset and sleep maintenance versus placebo at one month, is frequently referenced in formulary inclusion decisions [5].

Medicare Part D plans in California also cover Dayvigo, but with their own PA requirements and a different cost-sharing structure. During the coverage gap (the so-called "donut hole"), out-of-pocket costs for brand-name drugs like Dayvigo increase. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully in effect in 2025 and continuing into 2026, limits total exposure for Medicare beneficiaries [6].

For patients on Covered California marketplace plans, Dayvigo access depends on the specific metal tier (Bronze, Silver, Gold, Platinum) and the insurer selected. Higher-tier plans generally carry lower copays for brand-name drugs but higher monthly premiums. A 2023 systematic review in the Journal of Clinical Sleep Medicine found that dual orexin receptor antagonists like lemborexant showed consistent efficacy across patient subgroups, data that supports formulary inclusion arguments [7].

Is Compounded Lemborexant Legal in California?

Compounded lemborexant is available through licensed 503A compounding pharmacies in California under the oversight of the California State Board of Pharmacy. A 503A pharmacy compounds patient-specific prescriptions based on a valid prescriber-patient relationship. This is legal under both federal law (section 503A of the Federal Food, Drug, and Cosmetic Act) and California Business and Professions Code sections governing pharmacy compounding [8].

There are conditions. The compounding pharmacy must hold a valid California Board of Pharmacy license. The compounded product cannot be a copy of a commercially available drug in the exact same strength and dosage form unless the prescriber documents a clinical need for the compounded version (for example, a patient who cannot tolerate an inactive ingredient in the branded tablet). The FDA's guidance on 503A compounding outlines these distinctions [8].

Pricing for compounded lemborexant varies widely. Some 503A pharmacies in California offer compounded versions at significantly reduced cost compared to the branded product. Patients should verify that their pharmacy is licensed by checking the California Board of Pharmacy's online license lookup tool. Quality assurance standards differ between 503A pharmacies and conventional manufacturers, so discussing this option with your prescriber is appropriate.

Can I Get Dayvigo via Telehealth in California?

California permits telehealth prescribing of Dayvigo. A licensed prescriber (physician, nurse practitioner, or physician assistant with prescriptive authority under California law) can evaluate a patient via synchronous video or audio-only visit and, if clinically appropriate, prescribe lemborexant without an in-person examination. California's telehealth parity laws, codified under SB 510 and subsequent legislation, require insurers to cover telehealth visits at the same rate as in-person visits [9].

The American Academy of Sleep Medicine's position statement on telehealth endorses telehealth for the management of sleep disorders, including insomnia, noting that virtual consultations can effectively replace in-person visits for medication management and follow-up [9]. Platforms like HealthRX connect California patients with licensed clinicians who can prescribe Dayvigo after a telehealth evaluation and, if needed, coordinate prior authorization with the patient's insurance plan.

One practical note: California's Ryan Haight Act compliance requirements mean that online prescribers must hold a valid DEA registration if prescribing controlled substances. Lemborexant is a Schedule IV controlled substance under the federal Controlled Substances Act, and the DEA's scheduling determination applies in California [10].

What Does the Clinical Evidence Say About Lemborexant?

Dayvigo's efficacy rests on two registration trials. The SUNRISE-1 study (N=1,006) was a randomized, double-blind, placebo-controlled trial that measured objective sleep parameters using polysomnography. Lemborexant 5 mg reduced latency to persistent sleep by 10.5 minutes versus placebo (P<0.001), and lemborexant 10 mg reduced it by 12.5 minutes versus placebo (P<0.001) at one month [5].

The SUNRISE-2 study (N=949) examined patient-reported outcomes over 12 months. Patients receiving lemborexant 5 mg and 10 mg reported significantly improved subjective sleep onset latency and wake after sleep onset compared to placebo at six months, with sustained effects at 12 months [11]. Dr. Margaret Moline, the lead investigator, stated: "Lemborexant demonstrated sustained efficacy over 12 months with a safety profile consistent with short-term studies" [11].

Both trials enrolled adults aged 18 and older with insomnia disorder per DSM-5 criteria. The most common adverse effects were somnolence (reported in 7% of 10 mg recipients versus 1% of placebo recipients) and headache [1]. The FDA label carries a warning about next-morning impairment and advises patients not to drive or engage in activities requiring full alertness until they know how the drug affects them [1].

A 2021 network meta-analysis published in the Annals of Internal Medicine compared insomnia pharmacotherapies and found that dual orexin receptor antagonists (lemborexant and suvorexant) had favorable benefit-risk profiles compared to benzodiazepine receptor agonists like zolpidem, with lower rates of dependence and rebound insomnia [12]. The Endocrine Society's recommendations on sleep and metabolic health note that improving sleep quality through pharmacotherapy or CBT-I can positively affect metabolic biomarkers, a consideration relevant to California patients using insomnia treatment alongside GLP-1 or hormone therapy [13].

How to Get the Lowest Price on Dayvigo in California

Start with your insurance formulary. If Dayvigo is covered, apply the Eisai savings card on top to minimize your copay. If your plan does not cover Dayvigo or places it on a high-cost tier, ask your prescriber to submit a formulary exception request. Supporting clinical documentation (failed trials of other agents, documented insomnia severity) strengthens these requests.

For uninsured or underinsured patients, compare cash-pay prices at a minimum of three pharmacies using aggregator tools. Mail-order pharmacies sometimes offer meaningful discounts on 90-day fills. The NeedyMeds database lists patient assistance programs that may apply [14].

If your prescriber determines that compounded lemborexant is clinically appropriate, a licensed 503A pharmacy in California may offer lower pricing than the branded product. Always verify the pharmacy's license status through the California Board of Pharmacy. The California Board of Pharmacy's compounding regulations specify quality standards that licensed facilities must meet [8].

For Medicare Part D enrollees, the $2,000 annual out-of-pocket cap means that even if Dayvigo triggers the coverage gap, total annual exposure is capped. Patients approaching the cap early in the year should be aware that once the cap is reached, the plan covers 100% of remaining drug costs for the calendar year [6].

The average California patient filling Dayvigo monthly at $85 cash-pay spends $1,020 per year. With the Eisai savings card applied to a commercial plan, annual out-of-pocket costs often drop below $200.